Incyte Corporation (INCY) is a large-cap biopharmaceutical company with a market cap of $18.7 billion, focused on innovative therapeutics for oncology, hematology, and immune-related diseases. INCY stock has risen 14.8% in the past three months, outperforming the Nasdaq Composite. Long-term, INCY stock is up 38.1% YTD and 34.7% over the past 52 weeks. Incyte reported strong Q3 2025 results, beating expectations with adjusted EPS of $2.26 and total revenue of $1.37 billion. Analysts have a consensus rating of “Moderate Buy” for INCY with a mean price target of $101, representing a 5.9% premium.

Read more at Barchart: Is Incyte Stock Outperforming the Nasdaq?